CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China

Bulletin Express

Aug 28

Hong Kong-listed CSPC Pharmaceutical Group Limited (CSPC Pharma) announced on 28 August 2026 that the first study centre in Mainland China has formally activated the Phase II clinical trial (SYH2069-004) of SYH2069 Injection, a novel dual-target therapy for weight management in adults with overweight or obesity.

SYH2069 is a fatty acid-modified polypeptide designed to act as a long-acting dual-biased agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). By selectively activating the cyclic adenosine monophosphate (cAMP) pathway while avoiding β-arrestin-mediated receptor desensitisation, the candidate aims to enhance insulin-secretion, suppress appetite, delay gastric emptying, increase satiety and reduce caloric intake, thereby delivering combined glucose-lowering and weight-reducing effects.

Preclinical evaluations indicated favourable target activity and a manageable safety profile. Following receipt of a Clinical Trial Approval from the National Medical Products Administration in December 2025, CSPC Pharma completed Phase I trials that established preliminary safety and pharmacokinetic/pharmacodynamic characteristics in healthy participants with overweight or obesity.

The ongoing Phase II study is structured as a multicentre, randomised, double-blind, placebo-controlled trial focusing on non-diabetic individuals with obesity. Participant recruitment and screening are currently in progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1185285355"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185285355\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185285355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185285355","market":"us","top_or_hot":-1,"title":"CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China","media":"Bulletin Express","content":"<p>Hong Kong-listed CSPC Pharmaceutical Group Limited (CSPC Pharma) announced on 28 August 2026 that the first study centre in Mainland China has formally activated the Phase II clinical trial (SYH2069-004) of SYH2069 Injection, a novel dual-target therapy for weight management in adults with overweight or obesity.</p>\n<p>SYH2069 is a fatty acid-modified polypeptide designed to act as a long-acting dual-biased agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). By selectively activating the cyclic adenosine monophosphate (cAMP) pathway while avoiding β-arrestin-mediated receptor desensitisation, the candidate aims to enhance insulin-secretion, suppress appetite, delay gastric emptying, increase satiety and reduce caloric intake, thereby delivering combined glucose-lowering and weight-reducing effects.</p>\n<p>Preclinical evaluations indicated favourable target activity and a manageable safety profile. Following receipt of a Clinical Trial Approval from the National Medical Products Administration in December 2025, CSPC Pharma completed Phase I trials that established preliminary safety and pharmacokinetic/pharmacodynamic characteristics in healthy participants with overweight or obesity.</p>\n<p>The ongoing Phase II study is structured as a multicentre, randomised, double-blind, placebo-controlled trial focusing on non-diabetic individuals with obesity. Participant recruitment and screening are currently in progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-28 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed CSPC Pharmaceutical Group Limited (CSPC Pharma) announced on 28 August 2026 that the first study centre in Mainland China has formally activated the Phase II clinical trial (SYH2069-004) of SYH2069 Injection, a novel dual-target therapy for weight management in adults with overweight or obesity.</p>\n<p>SYH2069 is a fatty acid-modified polypeptide designed to act as a long-acting dual-biased agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). By selectively activating the cyclic adenosine monophosphate (cAMP) pathway while avoiding β-arrestin-mediated receptor desensitisation, the candidate aims to enhance insulin-secretion, suppress appetite, delay gastric emptying, increase satiety and reduce caloric intake, thereby delivering combined glucose-lowering and weight-reducing effects.</p>\n<p>Preclinical evaluations indicated favourable target activity and a manageable safety profile. Following receipt of a Clinical Trial Approval from the National Medical Products Administration in December 2025, CSPC Pharma completed Phase I trials that established preliminary safety and pharmacokinetic/pharmacodynamic characteristics in healthy participants with overweight or obesity.</p>\n<p>The ongoing Phase II study is structured as a multicentre, randomised, double-blind, placebo-controlled trial focusing on non-diabetic individuals with obesity. Participant recruitment and screening are currently in progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1185285355","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185285355","pubTimestamp":1787906964,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed CSPC Pharmaceutical Group Limited (CSPC Pharma) announced on 28 August 2026 that the first study centre in Mainland China has formally activated the Phase II clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团在中国启动SYH2069双重GLP-1/GIP激动剂肥胖管理II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"Hong Kong-listed CSPC Pharmaceutical Group Limited (CSPC Pharma) announced on 28 August 2026 that the first study centre in Mainland China has formally activated the Phase II clinical trial (SYH2069-004) of SYH2069 Injection, a novel dual-target therapy for weight management in adults with overweight or obesity.\nSYH2069 is a fatty acid-modified polypeptide designed to act as a long-acting dual-biased agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). By selectively activating the cyclic adenosine monophosphate (cAMP) pathway while avoiding β-arrestin-mediated receptor desensitisation, the candidate aims to enhance insulin-secretion, suppress appetite, delay gastric emptying, increase satiety and reduce caloric intake, thereby delivering combined glucose-lowering and weight-reducing effects.\nPreclinical evaluations indicated favourable target activity and a manageable safety profile. Following receipt of a Clinical Trial Approval from the National Medical Products Administration in December 2025, CSPC Pharma completed Phase I trials that established preliminary safety and pharmacokinetic/pharmacodynamic characteristics in healthy participants with overweight or obesity.\nThe ongoing Phase II study is structured as a multicentre, randomised, double-blind, placebo-controlled trial focusing on non-diabetic individuals with obesity. Participant recruitment and screening are currently in progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}